A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: In vitro and in vivo studies

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 1185-1196

  Zhang, Ting ^a   Zheng, Yong ^b   Peng, Qiang ^c   Cao, Xi ^a   Gong, Tao ^a   Zhang, Zhirong ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

Apoptosis; Cell uptake; Cytotoxicity; Ion pair complex; Submicron emulsion

Indexed keywords

OLEIC ACID; VINCRISTINE;

ANIMAL EXPERIMENT; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NANOEMULSION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT; ZETA POTENTIAL;

APOPTOSIS; CELL UPTAKE; CYTOTOXICITY; ION-PAIR COMPLEX; SUBMICRON EMULSION;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; DRUG CARRIERS; EMULSIONS; HUMANS; MALE; MCF-7 CELLS; OLEIC ACID; PARTICLE SIZE; RATS; RATS, WISTAR; SOLUBILITY; VINCRISTINE;

EID: 84875323041     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S41775     Document Type: Article

References (54)

1. Johnson IS, Armstrong JG, Gorman M, Burnett JP Jr. The vinca alkaloids: a new class of oncolytic agents. Cancer Res. 1963;23(8):1390-1427.
2. Gidding CEM, Kellie SJ, Kamps WA, de Graaf SSN. Vincristine revisited. Crit Rev Oncol Hematol. 1999;29(3):267-287.
3. Owellen RJ, Hartke CA, Dickerson RM, Hains FO. Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class. Cancer Res. 1976;36(4):1499-1453.
4. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res. 1991;51(8):2212-2222.
5. Lobert S, Vulevic B, Correia JJ. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry. 1996;35(21):6806-6814.
6. Lobert S, Frankfurter A, Correia JJ. Energetics of vinca alkaloid interactions with tubulin isotypes: implications for drug efficacy and toxicity. Cell Motil Cytoskeleton. 1998;39(2):107-121.
7. Lu X, Zhang F, Qin L, Xiao F, Liang W. Polymeric micelles as a drug delivery system enhance cytotoxicity of vinorelbine through more intercellular accumulation. Drug Deliv. 2010;17(4):255-262.
8. Harmon BV, Takano YS, Winterford CM, Potten CS. Cell death induced by vincristine in the intestinal crypts of mice and in a human Burkitt's lymphoma cell line. Cell Prolif. 1992;25(6):523-536.
9. Mohammad RM, Diwakaran H, Maki A, et al. Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leuk Res. 1995;19(9):667-673.
10. Wang JP, Kozo T, Tsuneji N, Yoshie M. Pharmacokinetics and antitumor effects of vincristine carried by microemulsions composed of PEG-lipid, oleic acid, vitamin E and cholesterol. Int J Pharm. 2003;251(1-2): 13-21.
11. Ling G, Zhang P, Zhang W, et al. Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. J Control Release. 2010;148(2): 241-248.
12. Waterhouse DN, Madden TD, Cullis PR, Bally MB, Mayer LD, Webb MS. Preparation, characterization, and biological analysis of liposomal formulations of vincristine. Methods Enzymol. 2005;391:40-57.
13. Allen TM, Newman MS, Woodle MC, Mayhew E, Uster PS. Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. Int J Cancer. 1995;62(2):199-204.
14. Chen J, Li S, Shen Q. Folic acid and cell-penetrating peptide conjugated PLGA-PEG bifunctional nanoparticles for vincristine sulfate delivery. Eur J Pharm Sci. 2012;47(2):430-443.
15. Noble S, Markham A. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Drugs. 1995;50(5):924-941.
16. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet. 2002;359(9308):741-746.
17. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2012;64 Suppl:175-193.
18. Klang SH, Frucht-Pery J, Hoffman A, Benita S. Physicochemical characterization and acute toxicity evaluation of a positively-charged submicron emulsion vehicle. J Pharm Pharmacol. 1994;46(12): 986-993.
19. Schwarz JS, Weisspapir MR, Friedman DI. Enhanced transdermal delivery of diazepam by submicron emulsion (SME) creams. Pharm Res. 1995;12(5):687-692.
20. Zhao D, Gong T, Fu Y, et al. Lyophilized Cheliensisin A submicron emulsion for intravenous injection: characterization, in vitro and in vivo antitumor effect. Int J Pharm. 2008;357(1-2):139-147.
21. Muchtar S, Almog S, Torracca M, Saettone M, Benita S. A submicron emulsion as ocular vehicle for delta-8-tetrahydrocannabinol: effect on intraocular pressure in rabbits. Ophthalmic Res. 1992;24(3): 142-149.
22. Ishida T, Maedaa R, Ichiharaa M, Irimurab K, Kiwada H. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J Control Release. 2003;88(1):35-42.
23. Ishida T, Masuda K, Ichikawa T, Ichihara M, Irimura K, Kiwada H. Accelerated clearance of a second injection of PEGylated liposomes in mice. Int J Pharm. 2003;255(1-2):167-174.
24. Ishida T, Ichihara M, Wang X, et al. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release. 2006;112(1):15-25.
25. Ishida T, Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm. 2008;354(1):56-62.
26. Skolnik JM, Barrett JS, Shi H, Adamson PC. A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer. Cancer Chemother Pharmacol. 2006;57(4):458-464.
27. D'Souza SS, DeLuca PP. Development of a dialysis in vitro release method for biodegradable microspheres. AAPS Pharm Sci Tech. 2005;6(2):E323-E328.
28. Liu S, Tong Y, Yang YY. Incorporation and in vitro release of doxorubicin in thermally sensitive micelles made from poly (N-isopropylacrylamide-co-N, N-dimethylacrylamide)-b-poly (D, L-lactide-co-glycolide) with varying compositions. Biomaterials. 2005;26(24):5064-5074.
29. Peng Q, Zhang ZR, Gong T, Chen GQ, Sun X. A rapid-acting, long-acting insulin formulation based on a phospholipid complex loaded PHBHHx nanoparticles. Biomaterials. 2012;33(5):1583-1588.
30. Galán-Malo P, Vela L, Gonzalo O, et al. Cell fate after mitotic arrest in different tumor cells is determined by the balance between slippage and apoptotic threshold. Toxicol Appl Pharmacol. 2012;258(3):384-393.
31. Pourroy B, Carré M, Honoré S, et al. Low concentrations of vinflunine induce apoptosis in human SK-N-SH neuroblastoma cells through a postmitotic G1 arrest and a mitochondrial pathway. Mol Pharmacol. 2004;66(3):580-591.
32. Higashiyama M, Inada K, Ohtori A, Kakehi K. NMR analysis of ion pair formation between timolol and sorbic acid in ophthalmic preparations. J Pharm Biomed Anal. 2007;43(4):1335-1342.
33. Choi SH, Park TG. Hydrophobic ion pair formation between leuprolide and sodium oleate for sustained release from biodegradable polymeric microspheres. Int J Pharm. 2000;203(1):193-202.
34. Alcock R, Blair J, O'Mahony D, Raoof A, Quirk A. Modifying the release of leuprolide from spray dried OED microparticles. J Control Release. 2002;82(2):429-440.
35. Pontes-Arruda A. Biological benefits of an oleic acid-rich lipid emulsion for parenteral nutrition. Clin Nutr Supp. 2009;4(1):19-23.
36. Quintanar-Guerrero D, Allémann E, Fessi H, Doelker E. Applications of the ion-pair concept to hydrophilic substances with special emphasis on peptides. Pharm Res. 1997;14(2):119-127.
37. Freitas C, Muller RH. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN) dispersions. Int J Pharm. 1998;168(2):221-229.
38. Aley K, Reichling D, Levine J. Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans. Neuroscience. 1996;73(1):259-265.
39. Authier N, Coudore F, Eschalier A, Fialip J. Pain related behaviour during vincristine-induced neuropathy in rats. Neuroreport. 1999;10(5): 965-968.
40. Weng HR, Cordella JV, Dougherty PM. Changes in sensory processing in the spinal dorsal horn accompany vincristine-induced hyperalgesia and allodynia. Pain. 2003;103(1-2):131-138.
41. Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain. 2004;109(1-2): 150-161.
42. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008;44(11):1507-1515.
43. Zhang J, Alter N, Reed JC, Borner C, Obeid LM, Hannun YA. Bcl-2 interrupts the ceramide-mediated pathway of cell death. Pro Natl Acad Sci U S A. 1996;93(11):5325-5328.
44. Zhang YF, Wang JC, Bian DY, Zhang X, Zhang Q. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Eur J Pharm Biopharm. 2010;74(3):467-473.
45. Owellen RJ, Owens AH, Donigian DW. The binding of vincristine, vinblastine and colchicine to tubulin. Biochem Biophys Res Commun. 1972;47(4):685-691.
46. Stewart ZA, Westfall MD, Pietenpol JA. Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci. 2003;24(3):139-145.
47. Chen YC, Lu PH, Pan SL, et al. Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways. Biochem Pharmacol. 2007;74(1):10-19.
48. Yuan X, Shan Y, Zhao Z, Chen J, Cong Y. G0/G1 arrest and apoptosis induced by SARS-CoV 3b protein in transfected cells. Virol J. 2005;2:66.
49. Hwang MS, Baek WK. Glucosamine induces autophagic cell death through the stimulation of ER stress in human glioma cancer cells. Biochem Biophys Res Commun. 2010;399(1):111-116.
50. Shu CH, Yang WK, Shih YL, Kuo ML, Huang TS. Cell cycle G2/M arrest and activation of cyclin-dependent kinases associated with low-dose paclitaxel-induced sub-G1 apoptosis. Apoptosis. 1997;2(5):463-470.
51. Emanuele S, Lauricella M, Carlisi D, et al. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis. 2007;12(7):1327-1338.
52. Vigers GA, Ziegler FD. Azide inhibition of mitochondrial ATPase. Biochem Biophys Res Commun. 1968;30(1):83-88.
53. Gabuzda D, Busciglio J, Chen LB, Matsudaira P, Yankner BA. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem. 1994;269(18):13623-13628.
54. Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release. 2010;145(3):182-195.